Physician profile
Asu Rustemli
NPI 1942452172
$2,285.57
in general payments reported to CMS, 2019-2025
25 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $107 · 2021: $95.78 · 2022: $156 · 2023: $272 · 2024: $597 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,409.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $391.79 | 2019-2024 | Aveir |
| Novartis Pharmaceuticals Corporation | $378.11 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $203.84 | 2019-2025 | Farxiga |
| Amgen INC. | $167.02 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $151.84 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $136.73 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.23 | 2019-2025 | Jardiance |
| Pfizer INC. | $116.21 | 2019-2024 | |
| Boston Scientific Corporation | $76.07 | 2019-2025 | Cds - Mct/Cem Monitoring |
| Kiniksa Pharmaceuticals International, Plc | $63.74 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.67 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $55.95 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $50.93 | 2019 | |
| Scpharmaceuticals INC. | $46.82 | 2024-2025 | |
| Edwards Lifesciences Corporation | $39.77 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $37.54 | 2020 | |
| Alnylam Pharmaceuticals INC. | $36.06 | 2025 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $28.32 | 2023-2024 | Camzyos |
| Baxter Healthcare | $26.86 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic Vascular, INC. | $19.96 | 2020 | |
| Lundbeck LLC | $18.73 | 2019 | |
| Lilly USA, LLC | $16.65 | 2025 | Zepbound |
| Medicure Pharma INC. | $13.76 | 2021 | |
| Abbvie INC. | $13.09 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asu Rustemli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.